Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review

被引:12
作者
Hashimoto, Kana [1 ]
Okuma, Yusuke [1 ,2 ]
Hosomi, Yukio [1 ]
Hishima, Tsunekazu [3 ]
机构
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan
[2] Jikei Univ, Sch Med, Res Ctr Med Sci, Div Oncol, Tokyo, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Pathol, Tokyo, Japan
关键词
Desmoplastic; Mesothelioma; Chemotherapy; Prognosis; PHASE-II; CARBOPLATIN; CISPLATIN; TUMORS;
D O I
10.1186/s12885-016-2745-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Desmoplastic malignant pleural mesothelioma (DMM) is rare histological subtype of diffuse malignant pleural mesothelioma (MPM), accounting for 5-10 % of cases. It has a poor prognosis, with direct invasion of the chest wall or lungs and distant metastases. Its pathological characteristics include dense collagen fibers in a storiform pattern. Its pretreatment pathological diagnosis is difficult, with fibrous pleuritis and reactive mesothelial hyperplasia as potential differential diagnoses. Case presentation: We retrospectively reviewed the medical charts of patients with MPM from 1996 to 2012. Among 60 patients with MPM, four patients with the desmoplastic subtype were identified and their clinical characteristics, including asbestos exposure, treatment, and prognosis, were reviewed. All of the patients with DMM were men, with a median age of 69 years (range: 63-74 years). All four patients had been exposed to asbestos. The definitive diagnosis was made histologically and the International Mesothelioma Interest Group classification was advanced (III/IV: 2/3) in all four patients. Three patients were treated with chemotherapy (two with cisplatin/pemetrexed and one with cisplatin/ gemcitabine) and one patient underwent surgery. The median survival time in the patients with DMM was 3.8 months (range: 0.9-11.5 months), compared with 10.5 months in patients with other subtypes of MPM in our institution. Conclusions: DMM continues to have a poor prognosis. It is important to recognize this variant and distinguish it from pleural plaques, non-specific reactive pleural fibrosis, pleurisy, and other lung diseases.
引用
收藏
页数:6
相关论文
共 27 条
[1]  
Aversa S M, 1999, Clin Lung Cancer, V1, P73, DOI 10.3816/CLC.1999.n.006
[2]  
Bianchi Claudio, 2014, Indian J Occup Environ Med, V18, P82, DOI 10.4103/0019-5278.146897
[3]   REACTIVE AND NEOPLASTIC SEROSAL TISSUE - A LIGHT-MICROSCOPIC, ULTRASTRUCTURAL, AND IMMUNOCYTOCHEMICAL STUDY [J].
BOLEN, JW ;
HAMMAR, SP ;
MCNUTT, MA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1986, 10 (01) :34-47
[4]   Modified RECIST criteria for assessment of response in malignant pleural mesothelioma [J].
Byrne, MJ ;
Nowak, AK .
ANNALS OF ONCOLOGY, 2004, 15 (02) :257-260
[5]   DESMOPLASTIC DIFFUSE MESOTHELIOMA [J].
CANTIN, R ;
ALJABI, M ;
MCCAUGHEY, WTE .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1982, 6 (03) :215-222
[6]   Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma [J].
Ceresoli, GL ;
Zucali, PA ;
Favaretto, AG ;
Grossi, F ;
Bidoli, P ;
Del Conte, G ;
Ceribelli, A ;
Bearz, A ;
Morenghi, E ;
Cavina, R ;
Marangolo, M ;
Parra, HJS ;
Santoro, A .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1443-1448
[7]   Malignant Pleural Mesothelioma [J].
Ettinger, David S. ;
Akerley, Wallace ;
Borghaei, Hossein ;
Chang, Andrew ;
Cheney, Richard T. ;
Chirieac, Lucian R. ;
D'Amico, Thomas A. ;
Demmy, Todd L. ;
Ganti, Apar Kishor P. ;
Govindan, Ramaswamy ;
Grannis, Frederic W., Jr. ;
Horn, Leora ;
Jahan, Thierry M. ;
Jahanzeb, Mohammad ;
Kessinger, Anne ;
Komaki, Ritsuko ;
Kong, Feng-Ming ;
Kris, Mark G. ;
Krug, Lee M. ;
Lennes, Inga T. ;
Loo, Billy W., Jr. ;
Martins, Renato ;
O'Malley, Janis ;
Osarogiagbon, Raymond U. ;
Otterson, Gregory A. ;
Patel, Jyoti D. ;
Pinder-Schenck, Mary ;
Pisters, Katherine M. ;
Reckamp, Karen ;
Riely, Gregory J. ;
Rohren, Eric ;
Swanson, Scott J. ;
Wood, Douglas E. ;
Yang, Stephen C. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (01) :26-41
[8]   Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma - A multicentric phase II study [J].
Favaretto, AG ;
Aversa, SML ;
Paccagnella, A ;
Manzini, VD ;
Palmisano, V ;
Oniga, F ;
Stefani, M ;
Rea, F ;
Bortolotti, L ;
Loreggian, L ;
Monfardini, S .
CANCER, 2003, 97 (11) :2791-2797
[9]   The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification [J].
Galateau-Salle, Francoise ;
Churg, Andrew ;
Roggli, Victor ;
Travis, William D. .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) :142-154
[10]   Histological typing of lung and pleural tumours: third edition [J].
Gibbs, AR ;
Thunnissen, FBJM .
JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (07) :498-499